Neurocrine Biosciences (NBIX) Q1 2026 Earnings
Neurocrine Biosciences reported Q1 2026 revenue of $814.5M (+42.2% YoY), beat analyst consensus of $768.3M by $46.2M. Diluted EPS came in at $1.94 (+2325.0% YoY), beat the $1.28 consensus by $0.66. Neurocrine Biosciences reports across 2 business segments, led by Commercial Products and Clinical Development Pipeline.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Neurocrine Biosciences's Q1 2026 earnings report.
Neurocrine Biosciences (NBIX) reported Q1 2026 earnings on May 5, 2026 after market close.
Neurocrine Biosciences reported revenue of $814.5M and diluted EPS of $1.94 for Q1 2026.
Revenue beat the consensus estimate of $768.3M by $46.2M. EPS beat the consensus estimate of $1.28 by $0.66.
Compared to the same quarter a year prior, revenue grew 42.2% from $572.6M a year earlier and diluted EPS grew 2325.0% from $0.08.
You can read the 8-K earnings release (0000914475-26-000025) and the 10-Q periodic report (0000914475-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.